ArcherDx specializes in advanced molecular biology technologies, particularly in the fields of genomics and gene editing. Their offerings include a wide range of custom and pre-designed oligonucleotides, such as DNA and RNA oligos, which can be tailored with over 1400 modifications to support various research applications. They provide high-quality reagents for PCR, qPCR, and dPCR, including specialized probes and master mixes designed for efficient and sensitive amplification. Additionally, ArcherDx is known for its CRISPR-Cas9 and CRISPR-Cas12a systems, which facilitate precise genome editing through optimized guide RNA libraries and Cas enzyme solutions, enhancing the capabilities of researchers in genetic engineering.

In the realm of next-generation sequencing (NGS), ArcherDx offers comprehensive library preparation kits and hybridization capture solutions, enabling researchers to conduct whole genome and exome sequencing, as well as targeted sequencing for specific applications like cancer research and infectious disease detection. Their products also include tools for gene synthesis, fragment generation, and assay development, which streamline workflows and improve the accuracy of genetic analyses. With a focus on high-throughput screening and regulatory compliance, ArcherDx supports a variety of applications, from biomarker discovery to therapeutic development, making significant contributions to the life sciences and biotechnology sectors.

United States

ArcherDX is developing and seeking regulatory clearances for next-generation sequencing (NGS) diagnostics to help solve for the underutilization of targeted cancer therapies.

ArcherDx

Company Details